MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE

Real-time Quotes | Nasdaq Last Sale

77.10
-0.03
-0.04%
Opening 12:19 05/25 EDT
OPEN
76.88
PREV CLOSE
77.13
HIGH
77.87
LOW
76.67
VOLUME
4.64M
TURNOVER
168.83M
52 WEEK HIGH
78.47
52 WEEK LOW
52.37
MARKET CAP
164.15B
P/E (TTM)
27.38
1D
5D
1M
3M
1Y
5Y
Karyopharm begins dosing in late-stage study of selinexor combo therapy for multiple myeloma
Karyopharm Therapeutics (NASDAQ:KPTI) and the European Myeloma Network (EMN), a collaboration of centers for multiple myeloma in Europe and Australia, said the first patient was dosed in the collaborative EMN29/XPORT-MM-031 study.
Seekingalpha · 3h ago
10 Recession-Proof Dividend Stocks to Buy
In this article, we discuss 10 recession-proof dividend stocks to buy. You can skip our detailed analysis of the stock market and its performance during recession, and go directly to see 5 Recession-Proof Dividend Stocks to Buy. The signs of an upcoming re...
Insider Monkey · 1d ago
Pfizer ulcerative colitis drug leads to remission in a third of patients -study
reuters.com · 1d ago
Analyzing Bristol-Myers Squibb's Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 10.76% since its last report. The company recently reported that it has 42.24 million shares sold short, which is 1.99% of all regular shares that are available for trading.
Benzinga · 1d ago
10 Stocks to Buy When Everyone is Selling
In this article, we discuss the 10 stocks to buy when everyone is selling. If you want to read about some more stocks to buy when everyone is selling, go directly to 5 Stocks to Buy When Everyone is Selling. On May 20, the benchmark S&P 500 Index fell 20% ...
Insider Monkey · 2d ago
Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Zacks · 2d ago
EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
Long-term agreement will enable the continued development and eventual construction and operation of the Texas solar park that will annually power the equivalent of more than 37,000 average homes
News Direct · 2d ago
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Zacks · 4d ago
More
No Data
Learn about the latest financial forecast of BMY. Analyze the recent business situations of Bristol-Myers Squibb Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
37.50%Buy
29.17%Hold
8.33%Under-perform
0.00%Sell
Analyst Price Target
The average BMY stock price target is 79.40 with a high estimate of 94.00 and a low estimate of 63.00.
High94.00
Average79.40
Low63.00
Current 77.74
EPS
Actual
Estimate
0.501.001.502.00
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 3.14K
Institutional Holdings: 1.76B
% Owned: 82.68%
Shares Outstanding: 2.13B
TypeInstitutionsShares
Increased
940
91.62M
New
188
30.95M
Decreased
954
74.02M
Sold Out
111
11.51M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.26%
Pharmaceuticals & Medical Research
-0.15%
Key Executives
Chairman/Chief Executive Officer/Director
Giovanni Caforio
Chief Financial Officer/Executive Vice President
David Elkins
Chief Human Resource Officer/Senior Vice President
Ann Powell
Executive Vice President/Chief Technology Officer
Greg Meyers
Executive Vice President/Chief Information Officer
Paul von Autenried
Executive Vice President/General Counsel
Sandra Leung
Executive Vice President
Christopher Boerner
Executive Vice President
Samit Hirawat
Executive Vice President
Elizabeth Mily
Executive Vice President
Louis Schmukler
Executive Vice President
Rupert Vessey
Executive Vice President
Michelle Weese
Senior Vice President/Controller
Sharon Greenlees
Senior Vice President
Joseph Eid
Lead Director/Independent Director
Theodore Samuels
Independent Director
Peter Arduini
Independent Director
Julia Haller
Independent Director
Manuel Medina
Independent Director
Paula Price
Independent Director
Derica Rice
Independent Director
Gerald Storch
Independent Director
Karen Vousden
Independent Director
Phyllis Yale
No Data
No Data
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Webull offers kinds of Bristol-Myers Squibb Co stock information, including NYSE:BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.